ni2o

ni2o is a neurotechnology company developing a sophisticated brain-computer interface (BCI) platform designed to address complex neurological and psychiatric disorders. The company's flagship technology, Newton, is a minimally invasive, AI-driven implantable device that monitors and modulates neural activity at the individual neuron level. By integrating advanced microelectronics with machine learning, ni2o aims to provide precise, real-time therapeutic interventions for conditions such as Parkinson's disease, Alzheimer's, and treatment-resistant depression. The platform is engineered to be significantly smaller and more capable than existing deep brain stimulation systems, potentially reducing surgical risks and improving patient outcomes. Headquartered in the Boston area, ni2o leverages collaborations with leading academic institutions like MIT and Oxford to advance the field of computational neuroscience.